SCHEMBL17616166

SCHEMBL17616166

COc1c(Cc2ccc(C)cc2)c(C)nc2c(C(=O)NC3CCCC3)cnn12

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.53
ALDH1A1 P00352 5/20 0.51
KDM4E B2RXH2 3/20 0.51
TSHR P16473 3/20 0.51
HPGD P15428 3/20 0.51
POLB P06746 1/20 0.51
CYP1A2 P05177 1/20 0.51
CYP2C19 P33261 1/20 0.51
TYK2 P29597 6/20 0.49
RUVBL1 Q9Y265 2/20 0.45
RUVBL2 Q9Y230 1/20 0.45
LMNA P02545 3/20 0.44
TP53 P04637 3/20 0.44
MAPT P10636 1/20 0.43
PDE4D Q08499 1/20 0.43
SPR P35270 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17616106 0.81 ALDH1A1 (0.53) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL4782268 0.75 MAPT (0.70) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL22957953 0.74 LMNA (0.44) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL902473 0.74 HSD17B10 (0.57) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL17616098 0.73 ALDH1A1 (0.67) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL22680752 0.73 LMNA (0.53) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL22957965 0.73 ALDH1A1 (0.51) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL17616095 0.71 LMNA (0.72) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL4940751 0.70 HSD17B10 (0.60) HSD17B10ALDH1A1KDM4ETSHRHPGD
SCHEMBL2464153 0.69 ALDH1A1 (0.80) HSD17B10ALDH1A1KDM4ETSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10912836-B2 Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer YALE UNIVERSITY (US) 2021-02-09 US disclosed
EP-2991677-B1 SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER UNIV YALE (US) 2020-07-15 EP disclosed
US-20190209696-A1 SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER UNIV YALE (US) 2019-07-11 US disclosed
US-20160082112-A1 SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2016-03-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10912836-B2 Synthetic antibody mimetic compounds (SyAMs) targeting cancer, especially prostate cancer CD47, FCGR1A, FCGR2A HSD17B10 4810/4885ALDH1A1 4223/4885KDM4E 1643/4885
US-20160082112-A1 SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER CD47, FCGR1A, FCGR2A HSD17B10 4789/4885ALDH1A1 3701/4885KDM4E 2155/4885
US-20190209696-A1 SYNTHETIC ANTIBODY MIMETIC COMPOUNDS (SYAMS) TARGETING CANCER, ESPECIALLY PROSTATE CANCER CD47, FCGR1A, FCGR2A HSD17B10 4810/4885ALDH1A1 4223/4885KDM4E 1643/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.